Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MGA271 |
Synonyms | |
Therapy Description |
MGA271 (enoblituzumab) is an inhibitory monoclonal antibody against CD276 (B7-H3), which induces an anti-tumor immune response (PMID: 22615450). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MGA271 | Enoblituzumab | CD276 Antibody 16 | MGA271 (enoblituzumab) is an inhibitory monoclonal antibody against CD276 (B7-H3), which induces an anti-tumor immune response (PMID: 22615450). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01391143 | Phase I | MGA271 | Safety Study of MGA271 in Refractory Cancer | Completed | USA | 0 |
NCT02923180 | Phase I | MGA271 | Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer | Active, not recruiting | USA | 0 |
NCT02982941 | Phase I | MGA271 | Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors | Completed | USA | 0 |
NCT06014255 | Phase II | MGA271 | Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer (HEAT) | Recruiting | USA | 0 |